share_log

Kura Oncology's Ziftomenib, Has Been Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory NPM1-mutant Acute Myeloid Leukemia

Benzinga ·  Apr 22 07:32
Kura Oncology's Ziftomenib, Has Been Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory NPM1-mutant Acute Myeloid Leukemia
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment